Search research articles
Contact Us
Filters
Showing results (191-200 of 773) with videos related to
Page
of 78
Sort By:
Mayo Clinic Proceedings
|
August 14, 2002
Current therapy for multiple myeloma
S Vincent Rajkumar, Morie A Gertz, Robert A Kyle, et al.
Cancer
|
February 19, 2008
Thromboembolic events with lenalidomide-based therapy for multiple myeloma
Smitha Patiyil Menon, S Vincent Rajkumar, Martha Lacy, et al.
Journal of the American Academy of Dermatology
|
March 29, 2003
Dermatologic side effects of thalidomide in patients with multiple myeloma
Virginia C Hall, Rokea A El-Azhary, Saskia Bouwhuis, et al.
American Journal of Hematology
|
May 6, 2009
Impact of vitamin D deficiency on the clinical presentation and prognosis of patients with newly diagnosed multiple myeloma
Alvin C Ng, Shaji K Kumar, S Vincent Rajkumar, et al.
Archives of Dermatology
|
October 18, 2006
Dermatologic adverse effects of lenalidomide therapy for amyloidosis and multiple myeloma
Hans P Sviggum, Mark D P Davis, S Vincent Rajkumar, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 21, 2005
Phase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: a clinical trial coordinated by the Eastern Cooperative Oncology Group
S Vincent Rajkumar, Emily Blood, David Vesole, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 23, 2009
Smoldering (asymptomatic) multiple myeloma: current diagnostic criteria, new predictors of outcome, and follow-up recommendations
Joan Bladé, Meletios Dimopoulos, Laura Rosiñol, et al.
Leukemia
|
April 24, 2025
Time for a paradigm shift in immunotherapy-based BCMA/CD3 bispecific drug development in multiple myeloma
Xavier Leleu, Arthur Bobin, Andre Herbelin, et al.
Leukemia Research
|
October 6, 2014
Multiple mechanisms contribute to the synergistic anti-myeloma activity of the pan-histone deacetylase inhibitor LBH589 and the rapalog RAD001
Vijay Ramakrishnan, Teresa Kimlinger, Michael Timm, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
December 11, 2002
Promising preclinical activity of 2-methoxyestradiol in multiple myeloma
David Dingli, Michael Timm, Stephen J Russell, et al.
Page
of 78
Search research articles
Search
Showing results (191-200 of 773) with videos related to
Sort By:
Page
of 78
Mayo Clinic Proceedings
|
August 14, 2002
Current therapy for multiple myeloma
S Vincent Rajkumar, Morie A Gertz, Robert A Kyle, et al.
Cancer
|
February 19, 2008
Thromboembolic events with lenalidomide-based therapy for multiple myeloma
Smitha Patiyil Menon, S Vincent Rajkumar, Martha Lacy, et al.
Journal of the American Academy of Dermatology
|
March 29, 2003
Dermatologic side effects of thalidomide in patients with multiple myeloma
Virginia C Hall, Rokea A El-Azhary, Saskia Bouwhuis, et al.
American Journal of Hematology
|
May 6, 2009
Impact of vitamin D deficiency on the clinical presentation and prognosis of patients with newly diagnosed multiple myeloma
Alvin C Ng, Shaji K Kumar, S Vincent Rajkumar, et al.
Archives of Dermatology
|
October 18, 2006
Dermatologic adverse effects of lenalidomide therapy for amyloidosis and multiple myeloma
Hans P Sviggum, Mark D P Davis, S Vincent Rajkumar, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 21, 2005
Phase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: a clinical trial coordinated by the Eastern Cooperative Oncology Group
S Vincent Rajkumar, Emily Blood, David Vesole, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 23, 2009
Smoldering (asymptomatic) multiple myeloma: current diagnostic criteria, new predictors of outcome, and follow-up recommendations
Joan Bladé, Meletios Dimopoulos, Laura Rosiñol, et al.
Leukemia
|
April 24, 2025
Time for a paradigm shift in immunotherapy-based BCMA/CD3 bispecific drug development in multiple myeloma
Xavier Leleu, Arthur Bobin, Andre Herbelin, et al.
Leukemia Research
|
October 6, 2014
Multiple mechanisms contribute to the synergistic anti-myeloma activity of the pan-histone deacetylase inhibitor LBH589 and the rapalog RAD001
Vijay Ramakrishnan, Teresa Kimlinger, Michael Timm, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
December 11, 2002
Promising preclinical activity of 2-methoxyestradiol in multiple myeloma
David Dingli, Michael Timm, Stephen J Russell, et al.
Page
of 78